Portal vein embolisation
Portal vein embolisation (PVE) is a technique used to selectively occlude the blood supply to one of the liver lobes diverting portal blood flow to the other lobe, allowing this future liver remnant (FLR). This will increase the size of the post hepatectomy future liver remnant (FLR) and improves surgical outcomes by preventing liver insufficiency.
PVE is a procedure performed by interventional radiology.
First published in 1990 by Makuuchi et al. 2
- FLR that would be too small for the patient's body mass, post hepatectomy (typically <20%)
- elevated ICG-R15 serum values 15 minutes after injection
- ICG (indocyanine green) binds to albumin and is excreted by the biliary system
- elevated values imply decreased hepatic reserve
- patients who underwent hepatotoxic chemotherapy, if FLR<30%
- cirrhosis, Child-Pugh class A, ICG-R15 <10%, if FLR <40%
- patients with hepatic steatosis
- concomitant pancreas resection and patients with diabetes due to poor post-hepatectomy hypertrophy rates
- ipsilateral portal tumour thrombus precluding catheter placement
- clinically overt portal hypertension (procedure exacerbates portal hypertension)
Can be performed on an outpatient basis. The FLR (on CT or MRI) should be obtained prior undertaking this procedure.
The right lobe is almost always targeted. The approach is usually through the right lobe, as well.
Different embolic agents have been used, including:
- n-butyl cyanoacrylate (NBCA)
- ethiodized oil
- fibrin glue
- microparticles (such as polyvinyl alcohol, PVA)
- microspheres followed by coils are used by some.
The portal vein can be approached surgically through a transileocolic approach, but interventional radiology usually approaches the portal vein transhepatically. Portal vein pressures are checked pre-procedure, to ensure that there is no portal hypertension.
- minor fluctuations in postprocedure liver function tests (50%)
- liver synthetic functions usually not affected
- nausea, fever, and pain are rare
- reported 0% procedure-related mortality 3
- reported overall morbidity of 2.2% 3
- nontarget embolization
- complete portal vein thrombus
- risks similar to other transhepatic procedures
Patients with otherwise normal livers regenerate two weeks postprocedure at 12-21 cm3 / day (9 cm3 / day for cirrhotic patients) 5. 2-4 weeks is usually enough for most patients with normal liver function (>4 weeks for patients with cirrhosis).
- 1. May BJ, Madoff DC. Portal vein embolization: rationale, technique, and current application. Semin Intervent Radiol. 2012;29 (02): 81-9. doi:10.1055/s-0032-1312568 - Free text at pubmed - Pubmed citation
- 2. Makuuchi M, Thai BL, Takayasu K et-al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990;107 (5): 521-7. Pubmed citation
- 3. Abulkhir A, Limongelli P, Healey AJ et-al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann. Surg. 2008;247 (1): 49-57. doi:10.1097/SLA.0b013e31815f6e5b - Pubmed citation
- 4. Denys A, Bize P, Demartines N et-al. Quality improvement for portal vein embolization. Cardiovasc Intervent Radiol. 2010;33 (3): 452-6. doi:10.1007/s00270-009-9737-x - Free text at pubmed - Pubmed citation
- 5. Madoff DC, Hicks ME, Vauthey JN et-al. Transhepatic portal vein embolization: anatomy, indications, and technical considerations. Radiographics. 2002;22 (5): 1063-76. doi:10.1148/radiographics.22.5.g02se161063 - Pubmed citation